comparemela.com

Latest Breaking News On - Immunoconjugates - Page 7 : comparemela.com

GT Biopharma Presented Preclinical Data Demonstrating Novel Mesothelin-Targeted TriKE® Driving Cytotoxicity Across All Stages of Non-Small Cell Lung Cancer at ESMO TAT 2022 | Antibodies

GT Biopharma Presented Preclinical Data Demonstrating Novel Mesothelin-Targeted TriKE® Driving Cytotoxicity Across All Stages of Non-Small Cell Lung Cancer at ESMO TAT 2022

United statesJeff millerGregory berkI gt biopharma incAnticancer therapies congressUniversity of minnesotaDriving cytotoxicity across all stagesNon small cell lung cancerUnited statesi marchChief medical officerTri specific killer engagerAstrolabe diagnosticsConsulting chief scientific officerBoard numberTherapeutic antibodiesAntibody drug conjugates

Eisai initiates submission of application data of lecanemab under the prior assessment consultation system in Japan with the aim of an earlier regulatory approval | Antibodies

Eisai initiates submission of application data of lecanemab under the prior assessment consultation system in Japan with the aim of an earlier regulatory approval

National institutes of healthNational institute onMinistry of healthDrug administrationDevices agencyAlzheimer clinical trial consortiumSwedeni marchNasdaq stockholmMedical devices agencyBiologics license applicationAccelerated approvalClinical trial consortiumNational instituteNational institutesBreakthrough therapyCommercialization agreement

Innovent Announces Two Registration Studies of IBI306 (anti-PCSK-9 antibody) Met Primary Endpoint | Antibodies

Innovent Announces Two Registration Studies of IBI306 (anti-PCSK-9 antibody) Met Primary Endpoint

United statesHong kongInnovent biologicsAdimab incyteYong huoEli lillyUniversity first hospitalChina cardiovascular healthNational medical products administrationMd anderson cancer centerI innovent biologics incInnovent announces two registration studiesMet primary endpointChinai februaryDrug evaluationPeking university first hospital

OSE Immunotherapeutics Announces Acceptance of the US Investigational New Drug (IND) Application Obtained by Veloxis Pharmaceuticals, Inc , its Partner in Transplantation, for CD28 Antagonist VEL-101/FR104 | Antibodies

OSE Immunotherapeutics Announces Acceptance of the US Investigational New Drug (IND) Application Obtained by Veloxis Pharmaceuticals, Inc., its Partner in Transplantation, for CD28 Antagonist VEL-101/FR104

United statesNorth carolinaDominique costantiniAsahi kaseiAsahi kasei groupNantes university hospitalVeloxis pharmaceuticals incBoehringer ingelheimFood drug administrationAnnounces acceptanceNew drugApplication obtainedVeloxis pharmaceuticalsFrancei januaryDrug administrationChief executive officer

First subject enrolled in phase II/III study of Eisai s anti-MTBR tau antibody E2814 for dominantly inherited Alzheimer s disease (DIAD), conducted by DIAN-TU | Antibodies

First subject enrolled in phase II/III study of Eisai s anti-MTBR tau antibody E2814 for dominantly inherited Alzheimer s disease (DIAD), conducted by DIAN-TU

Haruo naitoUniversity college londonI eisai co ltdNational institutes of healthNational institute onDrug administrationAlzheimer networkWashington university school of medicineAlzheimer network trials unitAlzheimer clinical trial consortiumJapani januaryWashington university schoolTau nexgenDominantly inherited alzheimer networkInherited alzheimerUniversity college

vimarsana © 2020. All Rights Reserved.